This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Type of economic evaluation
Cost-effectiveness analysis
Study objective
The study examined the clinical and economic impact of a large-scale HIV testing programme: the Expanded HIVTesting Initiative (EHTI) for populations disproportionally affected by HIV. The current economic evaluation was based on a financial return on investment (ROI) analysis.
Interventions
The objective of the EHTI was to increase HIV testing opportunities for populations disproportionately affected by HIV (primarily people who were ethnically black) and increase the proportion of people with HIV who were aware of their infection and linked to appropriate medical care and prevention services. The programme was implemented in 2007 by the Centers for Disease Control and Prevention (CDC).
The comparator was usual care before implementation of the programme.
Location/setting
USA/primary care.
Methods

Analytical approach:
The analysis was based on a published mathematical model of HIV transmission. It appeared that a lifetime horizon was used. Two perspectives were adopted: that of CDC and partners and that of the larger health care system (such as state and local governments).
Effectiveness data:
Clinical data for the model were mostly taken from the three-year period of programme implementation (2007 through 2009). The primary input of the analysis was the number of people newly infected with HIV who were identified through the programme. The background annual testing level used to calculate the number of infected persons identified in the absence of the programme was based on a previous CDC estimation. Other inputs were taken from published sources not fully described.
Monetary benefit and utility valuations:
Not considered.
Measure of benefit:
Number of HIV infections averted was the main endpoint of the programme. This was not combined with costs as a cost-consequences analysis was carried out. A 3% annual discount rate was used.
